Median Technologies Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Fredrik Brag

Algemeen directeur

€737.0k

Totale compensatie

Percentage CEO-salaris	54.3%
Dienstverband CEO	22.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Fredrik Brag's beloning veranderd ten opzichte van Median Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€25m
Mar 31 2024	n/a	n/a	-€24m
Dec 31 2023	€737k	€400k	-€23m
Sep 30 2023	n/a	n/a	-€22m
Jun 30 2023	n/a	n/a	-€21m
Mar 31 2023	n/a	n/a	-€21m
Dec 31 2022	€800k	€400k	-€20m
Sep 30 2022	n/a	n/a	-€19m
Jun 30 2022	n/a	n/a	-€19m
Mar 31 2022	n/a	n/a	-€19m
Dec 31 2021	n/a	n/a	-€19m
Sep 30 2021	n/a	n/a	-€18m
Jun 30 2021	n/a	n/a	-€18m
Mar 31 2021	n/a	n/a	-€15m
Dec 31 2020	n/a	n/a	-€13m
Sep 30 2020	n/a	n/a	-€11m
Jun 30 2020	n/a	n/a	-€8m
Mar 31 2020	n/a	n/a	-€8m
Dec 31 2019	€498k	€400k	-€8m
Sep 30 2019	n/a	n/a	-€9m
Jun 30 2019	n/a	n/a	-€11m
Mar 31 2019	n/a	n/a	-€13m
Dec 31 2018	€497k	€400k	-€15m
Sep 30 2018	n/a	n/a	-€16m
Jun 30 2018	n/a	n/a	-€17m
Mar 31 2018	n/a	n/a	-€17m
Dec 31 2017	€657k	€400k	-€17m

Compensatie versus markt: De totale vergoeding ($USD 773.51K ) Fredrik } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Fredrik is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Fredrik Brag

22.8yrs

Tenure

€737,000

Compensatie

Mr. Fredrik Brag founded Median Technologies S.A. in 2002 and served as its Chairman and President until April 2019 and serves as its Chief Executive Officer and General Manager. Mr. Brag has been Director...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Fredrik Brag	Founder	22.8yrs	€737.00k	geen gegevens
Jean-Christophe Montigny	Chief Financial Officer	3.3yrs	geen gegevens	geen gegevens
Marjorie Kooman	VP and Head of Investor & Media Relations	no data	geen gegevens	geen gegevens
Emmanuelle Leygues	Head of Corporate & Marketing Communications	no data	geen gegevens	geen gegevens
Chrystel Brun	Chief Human Resources Officer	1.8yrs	geen gegevens	geen gegevens
Ciaran Cooper	Head of Business Development	12.6yrs	geen gegevens	geen gegevens
Nicolas Dano	Chief Operating Officer of iCRO Business Unit	6yrs	geen gegevens	geen gegevens
Thomas Bonnefont	Chief Operating Officer & Chief Commercial Officer – eyonis™ Business Unit	3.7yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van 4ZG wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Fredrik Brag	Founder	5.6yrs	€737.00k	geen gegevens
Timothy Haines	Director	9yrs	geen gegevens	geen gegevens
Oran Muduroglu	Chairman of the Board of Directors	15.8yrs	€8.00k	geen gegevens
Oern Stuge	Director	4.4yrs	geen gegevens	geen gegevens
Kapil Dhingra	Director	12yrs	€50.00k	geen gegevens
Javier Zulueta	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens
Anil Vachani	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens
Carey Thomson	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens
David Yankelevitz	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens
Philippe Grenier	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens
Francesco Grossi	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens
Luis Maceiras	Member of Clinical Advisory Board for Lung Cancer Screening	2.1yrs	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4ZG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Median Technologies Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA, Annual General Meeting, Jun 20, 2023

No independent directors

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Recent updates

First half 2024 earnings released: €0.68 loss per share (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Median Technologies to Share Positive Pivotal Data for Eyonis LCS Diagnostic Software as Medical Device at the IASLC 2024 World Conference on Lung Cancer

Median Technologies Announces Pivotal Reality Study of Its Eyonis™? Lcs Lung Cancer Diagnostic Met All Primary and Secondary Endpoints

Median Technologies SA to Report First Half, 2024 Results on Oct 24, 2024

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.25 loss per share (vs €1.28 loss in FY 2022)

New major risk - Share price stability

New minor risk - Share price stability

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

No independent directors

Full year 2021 earnings released: €1.25 loss per share (vs €1.06 loss in FY 2020)

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd